We are thrilled to announce that Exeliom has been awarded €1.8M from Bpifrance as part of France’s Plan de Relance 2030🇫

This funding marks a significant milestone in our journey as it will fuel our expansion into immuno-oncology, with a substantial portion of this investment being allocated to three clinical trials that we initiated earlier this year.

The support from Bpifrance will also play a pivotal role in our efforts to scale-up operations, ensuring our readiness for commercialization on a broader scale.

We extend our deepest gratitude to Bpifrance for their unwavering support and vote of confidence in our vision.